All posts by imreal

When It Makes Sense To Drop Full Coverage


News Image

“In several cases, drivers can save car insurance money if they choose to drop the full coverage”, said Russell Rabichev, Marketing Director of Internet Marketing Company.

Policyholders are in control when they decide how much coverage they need. To avoid overpaying for coverage they don’t need, policyholders can choose to drop the full coverage. Drivers are recommended to drop full coverage in the following situations:


  • The car is too old. Even if the car is in perfect condition, its value will still decrease as time passes. If a car is older than 10 years, having full coverage is not worthy anymore.
  • The vehicle has high mileage. Even if a car is not old, if the odometer shows that it already traveled more than 200,000 miles, then the value of the car has dropped considerably. In this case, drivers should consider dropping full coverage.
  • The car is being financed. Drivers that are financing their cars are required by their lenders to have full coverage. Once the loan is paid, policyholders can choose to drop full coverage.
  • Full coverage might be too expensive for some drivers. When they can’t afford to pay for full coverage, they will probably choose to keep only the state’s minimum required insurance.
  • Policyholders that consider they are good drivers capable of not causing accidents, can save money by choosing to drop full coverage.

For additional info, money-saving tips and free car insurance quotes, visit http://compare-autoinsurance.org.

Compare-autoinsurance.org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc.

Share article on social media or email:

Tim O’Grady Promoted to President of American Portfolios Financial Services, Inc.


In his role as president, O’Grady acts as the eyes and ears of the firm, working collaboratively with all departments across all initiatives in order to grow the broker/dealer in all facets.

“Without question, Tim’s innate understanding of both the business and AP’s ethos can be attributed to our success over the years and I believe wholeheartedly he is the natural successor to take the broker/dealer into a new level of growth.”–CEO Lon T. Dolber

American Portfolios Financial Services, Inc. (AP) is pleased to formally announce that Tim O’Grady has officially assumed the role of president for the privately-held, independent broker/dealer (IBD), serving more than 700 producing investment professionals nationwide.

The promotion was informally announced to the firm’s affiliated colleagues this past October at AP’s annual national conference, Connections 2019, during CEO, CIO and former President Lon T. Dolber’s State of the Firm Address. Throughout his speech, Dolber spoke about the importance of succession planning—not just for its affiliated colleagues and their practices, but within its corporate leadership for those who are committed to keeping the firm sustainable and independent. “A company is not a great company if it depends on only one leader; everybody has to be relied upon for providing guidance and stewardship. For the last 15 years, we’ve been fortunate to have Tim with us for his ability to draw talented investment professionals to AP, zeroing in on their needs and giving them tools as business owners to operate successful, independent financial services practices. Without question, Tim’s innate understanding of both the business and AP’s ethos can be attributed to our success over the years and I believe wholeheartedly he is the natural successor to take the broker/dealer into a new level of growth.”

O’Grady began his tenure at AP as a consultant after attending one of the firm’s conferences, where he became convinced his acquired expertise could help the then-fledgling independent broker/dealer go far. He struck up a unique proposition with Dolber, initially refusing payment for his services in order to prove that his method of recruiting new talent was the right direction in which the firm should move. That unique proposition would pay dividends in no time. Through O’Grady’s sheer know-how, gift for relationship building, and measured and balanced negotiations dealings, he—and then with his expanding team—helped AP grow from a firm that now services over 700 producing investment professionals and their associates nationwide, with more than $30 billion in AUM. His leadership has also contributed to one of the firm’s proudest recognitions—being named Broker-Dealer of the Year* by Investment Advisor magazine for five consecutive years.

In his role as president of American Portfolios Financial Services, Inc., O’Grady acts as the eyes and ears of the firm, working collaboratively with all departments across all initiatives in order to grow the broker/dealer in all facets. More specifically, he works with the compliance area to handle the broker/dealer’s regulatory requirements outlined by FINRA and the SEC, and ensures the broker/dealer functions optimally from a customer relationship management standpoint. O’Grady serves as the main point of contact for the firm’s affiliated financial advisors, to arbitrate and/or advocate getting the services and support they need from AP in order to conduct business in a highly efficient and effective manner.

O’Grady continues to oversee all national sales development and recruiting for the firm, as well as supervising the Connections, regional, and Leaders Conference meetings for new and existing colleagues to ensure alignment. He and his team are responsible for all new business and branch development, which includes attracting new practices, as well as supporting the growth of existing offices.

AP possesses a finely-tuned operation that includes a tight-knit team of dedicated and skilled staff members in three areas: new business development – advisor relations, new business development – recruiting and focus partner relations.

Vice President of New Business Development and Advisor Relations David Molter oversees the team responsible for sales reporting, customer-facing initiatives and AP-affiliated, advisor-centered goals, which include: 1) Vice President of National Sales Kenneth Aulbach, whose main focus is on the overall development of advisory and broker/dealer sales, as well as recruiting; 2) Director of Practice Management Corey Brodsky, who interfaces with the AP advisor community to develop actionable plans to scale and grow their practices; 3) Director of Insurance Products Keith Carravone, who assists AP advisors on all types of annuities, life insurance, long term care and disability insurance; and 4) Business Consultants Thomas LoManto, Kaitlyn Stanley and Michael Boccio.

Working to bring recruiting to the next level is Director of New Business Development Carl Kirchner and New Business Development Consultant Mark Ferro, a former divisional sales manager for OppenheimerFunds.

Fostering and maintaining new and existing focus partner relationships is Director of Sales Operations Kristina Garrison and New Business Development Associate Denise Shaljian. The team is hard at work building out a robust, value-added meeting schedule for AP’s 2020 Connections Tour.

About American Portfolios

Headquartered in Holbrook, N.Y., American Portfolios Financial Services, Inc. (APFS) is a full-service, independent broker/dealer and member firm of FINRA and SIPC, offering a complete range of financial services, including personal financial and retirement planning, securities trading, mutual funds, access to investment research, long-term care planning, insurance products and tax-free investing. Fee-based asset management is offered through its sister subsidiary, American Portfolios Advisors, Inc., (APA), an SEC Registered Investment Advisor. Both entities, along with technology entity American Portfolios Advisory Solutions, LLC, collectively reside under the legal entity American Portfolios Holdings, Inc. (APH). Full-service securities brokerage is available through a clearing firm relationship with Pershing, LLC, a BNY Mellon firm, the securities of which are held on a fully disclosed basis. The company currently supports 826 independent investment professionals, to include registered assistants, as well as more than 375 non-registered associates, located in 396 branch locations throughout the nation. It was named Broker-Dealer of the Year* (Division III) by Investment Advisor magazine in 2015, 2016, 2017, 2018 and 2019; a wealthmanagement.com 2019 Industry Award Finalist in the category of Enhanced Customer Service Support**; one of the Best Companies to Work for in the state of New York for 2016, 2017, 2018 and 2019 by the New York State Society for Human Resources Management (NYS-SHRM) and the Best Companies Group (BCG); and one of the Top Long Island Workplaces for 2018 by Newsday.

*Based on a poll of registered representatives conducted by Investment Advisor magazine. Broker/dealers rated highest by their representatives are awarded “Broker/Dealer (B/D) of the Year.”

**Wealthmanagement.com Industry Award finalists are selected by a panel of independent judges made up of subject matter experts in the industry. Award is based on support provided to AP’s affiliated people and does not reflect public customers nor their account performance.

Share article on social media or email:

Workit Health’s Tele-MAT Digital Addiction Treatment Program Expands to Offer Medication for Alcohol Use Disorder


Workit Health members ready to reduce heavy drinking and cravings for alcohol in California, Michigan, and New Jersey can now meet with licensed clinicians via telemedicine and receive the FDA-approved medication naltrexone.

Today, Workit Health announced an expansion of its digital addiction care program to include medication for those ready to moderate or quit drinking. Workit Health members ready to reduce heavy drinking and cravings for alcohol in California, Michigan, and New Jersey can now meet with licensed clinicians via telemedicine and receive the FDA-approved medication naltrexone. The newly launched program helps members reach self-set recovery goals through online recovery groups, messaging with a care team, video visits with their dedicated clinician, and optional 1:1 online therapy.

The expansion to treat alcohol use disorder follows Workit Health’s successful opioid use disorder program, which began in Michigan in 2017 as a direct response to the opioid epidemic, and has since expanded to California and New Jersey. The digital program for opioid use disorder utilizes buprenorphine and includes online therapy via Workit Health’s web and phone apps after a single in-person appointment. Those ready to moderate or quit drinking will now be able to sign up and schedule their first appointment online, and continue all care via Workit Health’s web and phone apps from the privacy of their home.

“Although 15 million people in the U.S. struggle with alcohol use disorder, only 7% of those receive any sort of treatment. And despite being FDA-approved for alcohol dependence, naltrexone is not always available in traditional treatment programs,” said Lisa McLaughlin, Workit Health’s Co-CEO. “As people in recovery from alcohol use disorder ourselves, Robin and I are committed to expanding access to Workit Health’s discreet, convenient, and affordable digital care options that improve outcomes for individuals, health plans, and employers.”

“Despite the current focus on opioids, alcohol use disorder is the third leading preventable cause of death in the United States. Our success in treating opioid use disorder with medication via telehealth informs our decision to offer naltrexone for those ready to make a change to their relationship with alcohol,” Robin McIntosh, Workit Health’s Co-CEO, said. “We found that 84% of our members receiving medication for opioid use disorder were abstinent after 12 months – we’re looking forward to bringing these outcomes to the 15 million Americans struggling with alcohol.”

Naltrexone is clinically-proven to reduce heavy drinking days and comes in an oral tablet or monthly injection. Workit Health offers therapeutic courses and online recovery groups designed to help members reach their self-set recovery goals. The program includes two treatment types for naltrexone: The Sinclair Method, in which members take naltrexone before drinking to reduce the habit-forming reward effects of alcohol, or as a daily medication or monthly injection to reduce cravings for those who have quit drinking entirely. Clinical research illustrates that naltrexone treatment reduces relapses, the frequency and quantity of alcohol consumption for those who still drink, and alcohol cravings.

About Workit Health: Workit Health is a Joint Commission-accredited B-Corporation offering online, on-demand evidence-based addiction treatment including telemedicine medication for opioid and alcohol use disorders. We partner with healthcare organizations to deliver an innovative digital health solution that blends the best of human-centered design, technology, and science. Through our mobile and web apps, members meet with clinicians and counselors, join recovery groups, and complete self-set recovery goals. Our interactive curriculum of online courses keep members on track in the comfort of home. We offer 24/7 recovery that fits into daily life, designed by experts. For more information, visit http://www.workithealth.com.

Share article on social media or email:

Team Novo Nordisk Announces Partnership with FirstAid4Sport


Team Novo Nordisk named Firstaid4Sport as the official medical bag sponsor for the world’s first all-diabetes pro cycling team.

“We look forward to having the support of Firstaid4sport as we change diabetes. It is with their assistance through quality medical supplies that we are able to inspire, educate and empower everyone affected by diabetes,” said Phil Southerland, CEO & Co-Founder of Team Novo Nordisk.

Team Novo Nordisk, the world’s first all-diabetes professional cycling team, and UK-based Firstaid4sport announced a partnership naming the medical supplier as Team Novo Nordisk’s official medical bag sponsor.

In February 2019, the owners of Firstaid4sport’s son Max was rushed to the hospital. The then six-year-old boy was diagnosed with type 1 diabetes and received a Rufus Bear to help him learn how and where to inject insulin. When he was released from the hospital, Max set the goal of raising enough money to donate 200 Rufus Bears for newly diagnosed children throughout the UK. In addition to supporting Team Novo Nordisk, Firstaid4sport donates a percent of sales from its MAXTape to JDRF.

“The Team Novo Nordisk and Firstaid4sport partnership is a personal one. Diabetes only chooses the champions and it is clear that Max is definitely a champion. It is empowering to see kids as young as Max already motivated to give back to the diabetes community,” Team Novo Nordisk CEO and Co-Founder Phil Southerland said. “We look forward to having the support of Firstaid4sport as we travel the world changing diabetes. It is with their assistance through quality medical supplies that we are able to inspire, educate and empower everyone affected by diabetes.”

The family-run Firstaid4sport was born after its director Gemma Davison tried to provide treatment to an injured hockey player and struggled to find the first aid kit amongst the mass of black bags brought by the team. Upon finding the kit, Gemma realized the contents were not appropriate to treat the injury.

Fifteen years later, Firstaid4sport provides bright orange medical bags complete with sport-specific first aid kits to sporting medical professionals and enthusiasts to prevent and treat injuries quickly, which allows for faster recovery. Firstaid4sport supplies a range of clubs from Super League Club Huddersfield Giants to England Dodgeball with medical bags, but no matter what size or stature the club, they always receive the same quality products and excellent customer service. To Firstaid4sport, safety in sport is paramount no matter what level you compete at.

“Firstaid4sport is incredibly proud to become the medical bag partner of Team Novo Nordisk and we look forward to supporting the team throughout the season. Team Novo Nordisk’s mission to inspire, educate and empower everyone affected by diabetes is something close to our mission of raising money for the JDRF through the sales of our Max Tape,” Firstaid4sport Business Development Manager Catherine Gray said. “This partnership will ensure that the team has access to the highest quality medical supplies ensuring every rider will be protected throughout every race.”

About Team Novo Nordisk

Team Novo Nordisk is a global all-diabetes sports team of cyclists spearheaded by the world’s first all-diabetes professional cycling team. In 2012, Phil Southerland, co-founder and CEO of the team, and global healthcare company Novo Nordisk, came together to create Team Novo Nordisk, based on a shared vision to inspire, educate and empower people around the world affected by diabetes. For more information, go to http://www.teamnovonordisk.com.

Share article on social media or email:

Vendavo Launches New Updates for Enterprise Profitability Solutions


News Image

VEPS10 is the latest edition of the Vendavo Enterprise Profitability Solution and is part of the broader set of solutions that make up the Commercial Excellence solution suite.

Many B2B enterprises sell tens of thousands or even millions of products and updating all those prices with ever-changing market conditions and growing customer expectations with an eye toward profitability seems insurmountable. To enable the effective operationalization of more advanced pricing strategies and maximize every margin moment, Vendavo, the market leader in commercial excellence solutions, today launched the latest update for Vendavo Enterprise Profitability Solutions (VEPS).

“For very large organizations who need a highly configurable pricing solution for their unique enterprise environments, VEPS is the perfect fit,” said Alex Hoff, VP Product Management and Marketing, Vendavo. “Vendavo remains committed to offering enterprises the choice of highly configurable solutions that are easy to use, more secure, and higher performing while also delivering additional cloud-based solutions that are quick to scale and dynamic.”

VEPS10 is the latest edition of the Vendavo Enterprise Profitability Solution and is part of the broader set of solutions that make up the Commercial Excellence solution suite. It includes: Profit Analyzer, Deal Manager, Deal Guide, Price Manager, Segmentation Manager, Price Optimization Manager, and Business Risk Alerts. Other complimentary solutions include CPQ Cloud for quoting and sales effectiveness, PricePoint for dynamic price management and Deal Price Guidance for intelligent pricing guidance delivered to quoting systems.

As part of the continued innovation and investment in VEPS, Vendavo is reducing common barriers in implementation and adoption. As an example, Deal Manager and Deal Guide – the sales-role focused VEPS solutions that deliver pricing insights to the field – are easily deployed for customers using Salesforce® as their CRM by utilizing the Vendavo® Deal Manager Extension for Salesforce® listed on the Salesforce AppExchange.

Additionally, Vendavo PricePoint, Vendavo Pricing Guidance and Vendavo Profit Insights — all also a part of the Vendavo Commercial Excellence Platform — are now available for digital and online purchase on the SAP App Center for ERP and SAP S/4HANA. They are specifically designed to increase sales velocity and expedite business-value generation. This added ease of integration with SAP applications allows organizations to accelerate the capture of greater profit opportunity across their deal-making processes.

A SaaS solution, VEPS is hosted and managed in the Vendavo cloud and has been upgraded for modern browser support including Chrome and Safari. It contains important security and performance improvements, and a more modern architecture for an even lower total cost of ownership.

Supporting Resources:

About Vendavo

Vendavo powers the shift to digital business for the world’s most demanding B2B companies, unlocking value, growing margin and accelerating revenue. With the Vendavo Commercial Excellence platform, companies develop dynamic customer insights and optimal pricing strategies that maximize margin, boost sales effectiveness and improve customer experience. With an annual margin improvement totaling more than $2.5 billion across companies in chemicals, distribution, high-tech and manufacturing, Vendavo delivers cutting-edge analytics and deep industry expertise that help companies stay one step ahead. Vendavo is headquartered in Denver, CO and has offices around the globe. Learn more at Vendavo.com.

Share article on social media or email:

Ikonix USA Brands Will be Attending the Strategies in Light Show


Strategies in Light

Ikonix USA is pleased to announce their attendance at this year’s Strategies in Light Show; SCI and Associated Power Technologies will be exhibiting. The show will take place February 11th – February 13th at the San Diego Convention Center in San Diego, California. Ikonix USA brands will be showcasing a variety of instruments appealing to the lighting and LED industries. SCI will be presenting the New 440 Model and Associated Power Technologies will be showing the 6010 Model. Ikonix USA can be found at Booth #1116.

Product Features

SCI

  • 440 Model: 4-in-1 electrical safety tester capable of performing AC/DC Hipot, Insulation Resistance and Ground Bond tests. The all in on capability allows LED and Lighting manufactures to achieve all necessary testing standards. Features include SmartGFI® function for operator safety as well as safety interlock. The 440 Series offers up-to 20 programmable memories, comes with standard USB port for automation and data collection, as well as PLC control capability.

Associated Power Technologies

  • 6010 Model: Ideal for advanced applications. Switch-mode technology and a direct coupled output makes the 6010 lightweight and efficient for use on the bench-top or rack mount applications. Optional DC Output Voltage allows the operator to get even more range out of the programmable Power Source. Pair the source with PowerTRAC™ software to calculate Watt Hours, easily gather data, and analyze test results performed by the 6000 Series.

For further information about this year’s Strategies in Light Show, please visit their site at https://www.strategiesinlight.com/sil2020/320032

Contact the company at 1-847-367-4077 or visit their site at http://www.ikonixusa.com. For editorial questions, please contact Amanda Boothe at amanda.boothe@ikonixusa.com.

Share article on social media or email:

Electronic Health Records Software Users Review Vendors for Satisfaction, Revealing Their Top Three Through SoftwareReviews


2020 GRC Emotional Footprint Awards

SoftwareReviews, a division of world-class IT research and consulting firm Info-Tech Research Group, has published its 2020 Electronic Health Records (EHR) Data Quadrant Awards, naming three gold medalists based on excellent user reviews. The following vendors are leaders according to software users’ answers to some very interesting questions focused on user satisfaction, which have been crafted by seasoned IT industry analysts and backed by 22 years of IT research:


  • Epic (EpicCare)
  • Allscripts Healthcare Solutions Inc. (McKesson Paragon EHR)
  • Athenahealth (AthenaClinicals)

What makes the SoftwareReviews Data Quadrant different is the inclusion of aggregated emotional response ratings in the areas of service, negotiation, product impact, conflict resolution, and strategy and innovation. These ratings create a powerful indicator of overall user feeling toward the vendor and its product from the software users’ point of view. SoftwareReviews calls this insight the Net Emotional Footprint.

EpicCare ranked highest among software users, earning the number-one spot in the areas of breadth of features, quality of features, ease of data integration, charting, healthcare reporting and analytics, patient portal, customer relationship management, as well as product strategy and rate of improvement. McKesson Paragon EHR users were exceedingly satisfied, giving the vendor top scores in many areas, including business value created, ease of IT administration, ease of customization, ease of implementation, claims processing, clinical flow, lab integration, and telemedicine. AthenaClinicals performed consistently well according to software users, taking the number-one spot for appointment management.

About SoftwareReviews Data Quadrant Awards and Software Reports

SoftwareReviews Data Quadrant Awards recognize outstanding vendors in the technology marketplace as evaluated by their users annually. Top vendors in a software category are eligible to receive Data Quadrant Gold Medals, provided their net-promoter scores meet the threshold for sufficiently high user satisfaction across four areas of evaluation: vendor capabilities, product features, likeliness to recommend, and vendor experience. In-depth product evaluation reports are available at http://www.softwarereviews.com.

About SoftwareReviews

SoftwareReviews is a division of Info-Tech Research Group, a world-class IT research and consulting firm established in 1997. Backed by two decades of IT research and advisory experience, SoftwareReviews is a leading source of expertise and insight into the enterprise software landscape and client-vendor relationships.

By collecting real data from IT and business professionals, the SoftwareReviews methodology produces the most detailed and authentic insights into the experience of evaluating and purchasing enterprise software.

For more information, please contact:

Leanne O’Brien

Director, Communications & PR

lobrien@infotech.com

1-888-670-8889 ext. 3409

Share article on social media or email:

Texas Senator Larry Taylor joins Chevron, SABIC, BP, BASF execs to discuss workforce development challenges in Gulf Coast conference


Since 2010, petrochemical producers have announced significant expansions of capacity in the U.S., and the momentum is not over

Petrochemical Update, part of Reuters Events, today confirmed Texas Senator Larry Taylor (R-Friendswood) will join senior executives from Chevron, SABIC, BP and BASF at Downstream 2020.

Senator Taylor and the other leaders will be attending the world’s biggest downstream event to discuss key industry issues including the workforce challenges currently facing the sector and the opportunities presented by the second wave of investment currently underway in the Gulf Coast.

The Downstream 2020 Exhibition & Conference features 450 exhibition stands and is expected to attract more than 10,000 attendees and 3,000 conference delegates. The 2019 event generated more than $60 million in new business for attendees.

Alongside Senator Taylor, confirmed speakers for the 2020 event so far include:


  • SABIC’s general manager of global engineering and project management, Jim Ellis.
  • BASF’s director of supply chain petrochemicals in North America, Bret Bement.
  • BP’s global petrochemical operational excellence manager, Walter Pesenti.
  • Chevron’s Pasadena refinery general manager, Tim Sutherland.
  • Freeport LNG’s vice president of projects, Taylor Auburg.
  • Meridian Energy’s chief technology officer, Mark Fonda.

Over two days, Downstream 2020 will feature conference tracks on process engineering, engineering and construction, reliability and maintenance, shutdowns and turnaround, and supply chain and logistics.

“Since 2010, petrochemical producers have announced significant expansions of capacity in the U.S., and the momentum is not over,” said Downstream 2020 global project director Bridget Robinson.

“To date, 334 chemical and plastics projects cumulatively valued at $204 billion have been announced, with 53% of the investment completed or underway and 40% in the planning phase. Downstream 2020 represents a unique opportunity to tap into this vibrant and growing market.”

Petrochemical Update is now part of Reuters Events, after its parent company FC Business Intelligence was acquired as part of the Reuters news and media division of Thomson Reuters in October 2019.

For more information about Downstream 2020, taking place on June 10 and 11 at the NRG Center, Houston, download the event brochure or write to sasha@petchem-update.com.

Share article on social media or email:

Oral Surgery San Francisco Announces Informational Post about Wisdom Teeth Removal and Being Pro-active for 2020


San Francisco Oral Surgery is proud to announce a new post for taking the leap and scheduling wisdom tooth removal for the New Year.

Oral Surgery in San Francisco

Many New Year’s resolutions are broken because they aren’t considered ‘fun’ or ‘easy.

San Francisco Oral Surgery, a team of best-in-class oral surgeons in San Francisco, California, is proud to announce a new post about managing wisdom tooth removal early in 2020. Impacted wisdom teeth can cause discomfort and progress into serious health issues. Before wisdom teeth become a daily painful distraction, San Francisco residents can schedule oral surgery early in the year. The proactive approach to oral surgery might increase the opportunity for a healthier, happier year.

“Many New Year’s resolutions are broken because they aren’t considered ‘fun’ or ‘easy.’ We know oral surgery isn’t someone’s idea of a great way to begin the year, but it could be the healthiest,” explained San Francisco oral surgeon Dr. Alex Rabinovich. “Early removal of wisdom teeth can help avoid serious mouth problems later. Our new post explains the value of scheduling oral surgery soon so a person can move on to other goals. We’ll do our best to make sure it’s an easy and comfortable process!”

San Francisco Bay Area residents can review the new post from Oral Surgery San Francisco at https://www.oralsurgery-sf.com/2019/11/oral-surgery-is-serious-so-you-need-the-very-best-oral-surgeon/. Locals can also review details about oral surgery in San Francisco at the wisdom teeth page https://www.oralsurgery-sf.com/wisdom-teeth/. Anyone interested in more information can schedule a consultation with an oral surgeon via the website.

ORAL SURGERY PROFESSIONALS IN SAN FRANCISCO HELP LOCALS TAKE THE INITIATIVE EARLY IN 2020

Here is the background on this release. New Year’s resolutions can include setting new self-improvement goals for 2020. Removing impacted wisdom teeth early in the year can help avoid oral problems later. Erupted third molars can cause serious oral problems, including the following: chewing difficulty, mouth pain, and bacterial infections. Scheduling a visit with a professional oral surgeon early in the year could help avoid oral pain and health complications later. For these reasons, oral surgery San Francisco has announced a new blog post for the New Year that includes a ‘2020 checklist’ of new goals for Bay Area locals. Important goals can include scheduling wisdom tooth surgery to improve one’s oral health.

ABOUT ORAL SURGERY SAN FRANCISCO

Oral Surgery San Francisco is located in the Financial District of the City and on the web at https://www.oralsurgery-sf.com/. It is under the direction of Dr. Alex Rabinovich, a Board Certified Oral and Maxillofacial Surgeon specializing in the field of oral surgery. This additional training, along with his years of experience, sets Alex Rabinovich apart from the growing number of general dentists offering oral surgery and other dental procedures. The cost of oral surgery can be expensive yet the clinic accepts over forty types of insurance plans from Bay Area employers. Oral surgery options include wisdom teeth extraction, jaw surgery, and dental implants. Oral Surgery San Francisco serves all neighborhoods in the city of San Francisco, including Pacific Heights, Russian Hill, and Noe Valley.

Share article on social media or email:

In Vitro Diagnostics Brought to Bear


Kalorama Information logo

Today’s test menus cannot be static. Infections appear or they enter markets they are not expected in. Even large panels with scores of tests won’t cover everything.

The recent novel coronavirus, responsible for over 100 deaths in the Hubei province in China at the time of writing, undermines any notion of a known quantity of infectious disease threats in the world that lab analyzer menus will remain adequate, according to IVD market research Kalorama Information. Swine flu, Ebola, and Zika were reminders that laboratories need to be vigilant and that in vitro diagnostic test makers must constantly update assays that providers can use to identify threats.

“Today’s test menus cannot be static,” said Bruce Carlson, publisher of Kalorama Information. “Infections appear or they enter markets they are not expected in. Even large panels with scores of tests won’t cover everything.”

Diagnostic tools such as reverse transcription polymerase chain reaction (RT-PCR) and sequencers have been used in characterizing and identifying the virus, and new tests are in development. IVD vendors are supporting efforts. Meridian Bioscience announced that its freeze-dried Lyo-Ready 1-Step RT q-PCR mix is being used in the coronavirus outbreak in China.

Kalorama Information projects the infectious disease IVD testing market to be worth more than $18 billion, according to its latest complete world infectious disease market research report, with revenue growth higher than the 4% of normal testing markets.

The new virus — dubbed 2019-nCoV — has already been sequenced, and Chinese health authorities have posted the full genome via the Global Initiative on Sharing All Influenza Data (GISAID) portal, which collects information on respiratory diseases. This allowed other researchers to quickly detect the RNA mechanisms of the virus and develop novel detection methods. Using this information, the U.S. Centers for Disease Control and Prevention (CDC) has developed its own real-time PCR test.

Study of the genetic code revealed that the novel betacoronavirus is in the same virus family as severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV); in those diseases, bats were the source. The name coronavirus comes from the virus’ crown-shaped appearance when viewed in electron microscopy, and, indeed, the shape appears to be a significant detail. It is believed that the heavily glycosylated “spike” protein helps it fuse with host cell membranes, assisting the virus to spread to host cells.

At the time of writing, the CDC laboratory in Atlanta was the only U.S. lab indicated to complete viral isolation and perform real-time PCR to diagnose 2019-nCoV; however, the agency has distributed test protocols and plans to make reagents available. For cases of suspected coronavirus in patients having recently traveled to affected regions, the CDC procedures call for the collection of sputum, nasopharyngeal swabs, and blood.

Currently, no testing kits specifically for 2019-nCoV are commercially available. On January 23, Altona Diagnostics announced it was in the process of developing a molecular diagnostic assay for detecting 2019-nCoV in close cooperation with major reference institutes for emerging diseases. Altona Diagnostics was one of the first companies to make reliable molecular diagnostic kits commercially available during outbreaks of SARS-CoV, MERS-CoV, and the Ebola and Zika viruses, among others.

Also, molecular diagnostics maker Co-Diagnostics announced several days ago that it has completed design work for a PCR screening test for the new virus.

If experiences with the Ebola and Zika viruses are any indication, IVD vendors will be at work modifying test technologies and developing tests for emergency approval.

Roche and Chembio Diagnostic Systems were among the vendors to produce emergency use authorization (EUA) tests for Ebola. A number of coronavirus MERS tests are on the market — including Siemens Fast Track, Seegene Anyplex, Roche LightMix, and Bio-Rad CFX96 — and the manufacturers are in a good position to adapt their technology for related novel viruses. Abbott Laboratories indicated that it is actively monitoring the 2019-nCoV outbreak in a recent podcast.

Kalorama Information’s Infectious Disease Diagnostics World Market Analysis: HIV/AIDS, Hepatitis, Tuberculosis, STDs, HAIs, ID/AST, Influenza, TORCH, Other report contains market sizing for every major country market in the world. https://kaloramainformation.com/product/infectious-disease-diagnostics-world-market-analysis/

Data provided include the following:


  • Global Infectious Disease IVD Demand by Country/Region 2018 – 2026 (million dollars) (North America: United States, Canada & Mexico; Western Europe; Asia/Pacific: China, Japan, Other; Cent & So America; Eastern Europe; Middle East; Africa; Total World)
  • North America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total N Amer)
  • United States – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total US)
  • Canada – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Canada)
  • Mexico – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Mexico)
  • Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total W. Europe)
  • Germany – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Germany)
  • France – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total France)
  • United Kingdom – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total UK)
  • Italy – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Italy)
  • Spain – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Spain)
  • Other Western Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total OWE)
  • Other Western Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Netherlands, Belgium, Austria, Sweden, Switzerland, Denmark, Portugal, Norway, Greece, Ireland, Finland, All Other)
  • Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Asia/Pacific)
  • China – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total China)
  • Japan – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Japan)
  • India – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total India)
  • South Korea – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total South Korea)
  • Australia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Australia)
  • Other Asia/Pacific – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Other Asia/Pacific)
  • Other Asia/Pacific – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Indonesia, Taiwan, Thailand, Philippines, Vietnam, Malaysia, Pakistan, Hong Kong, Singapore, New Zealand, All Other)
  • Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total C & S Amer)
  • Brazil – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Brazil)
  • Other Central & South America – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Cent & So Amer)
  • Other Central & South America – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Argentina, Colombia, Chile, Peru, Venezuela, All Other)
  • Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total E Europe)
  • Russia – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Russia)
  • Other Eastern Europe – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other E. Europe)
  • Other Eastern Europe – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Poland, Romania, Czechia, Ukraine, Hungary, All Other)
  • Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Middle East)
  • Turkey – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Turkey)
  • Other Middle East – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Other Middle East)
  • Other Middle East – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Iran, Saudi Arabia, Iraq, Israel, UAE, All Other)
  • Africa – Infectious Disease IVD Demand by Product Group 2018 – 2026 (million dollars) (STDs, Hepatitis, HIV/AIDS, HAIs, ID/AST, Influenza, Tuberculosis, TORCH, Other, Total Africa)
  • Africa – Infectious Disease IVD Demand by Country 2018 – 2026 (million dollars) (Egypt, South Africa, Nigeria, All Other)

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email: